Metabolic alterations in plasma from patients with familial and idiopathic Parkinson’s disease
Open accessAbstract
gene) Parkinson's disease, as well as, from mice treated with 6-hydroxydopamine to induce Parkinson disease. Both human and murine Parkinson was accompanied by an increase in plasma levels of unconjugated bile acids (cholic acid, deoxycholic acid and lithocholic acid) and purine base intermediary metabolites, in particular hypoxanthine. The comprehensive metabolomic analysis of plasma from Parkinsonian patients underscores the importance of bile acids and purine metabolism in the pathophysiology of this disease. Therefore, plasma measurements of certain metabolites related to these pathways might contribute to the diagnosis of Parkinson's Disease.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Elevated levels of secondary bile acids are found in PD patients, while findings regarding primary bile acids have yielded varying results.
“Studies have revealed elevated levels of secondary BAs in PD patients, while findings regarding primary BAs have yielded varying results.377–380”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [380]
An elevated level of primary bile acid cholic acid is identified in the plasma of PD patients.
“An elevated level of primary BA (cholic acid) was identified in the plasma of PD patients.379,380”
From Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases (2024) · cites this paper as [380]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
The Mouse Brain in Stereotaxic Coordinates
Paxinos, G. (2001) · Cited by 12,859 · see citing works
Metabolomics: beyond biomarkers and towards mechanisms
Johnson, C. H., Ivanisevic, J., & Siuzdak, G. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2016.25 · Cited by 2,829 · see citing works
Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease
Paisán‐Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simón, J., van der Brug, M., de Munaín, A. L., Aparicio, S. F., Gil, A. M., Khan, N. L., et al. (2004) · Neuron · doi:10.1016/j.neuron.2004.10.023 · Cited by 2,416 · see citing works
Self-citationLang, A. E., & Lozano, A. M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810083391506 · Cited by 2,041 · see citing works
Healy, D. G., Falchi, M., O’Sullivan, S. S., Bonifati, V., Dürr, A., Bressman, S., Brice, A., Aasly, J. O., Zabetian, C. P., Goldwurm, S., et al. (2008) · The Lancet Neurology · doi:10.1016/s1474-4422(08)70117-0 · Cited by 1,523 · see citing works
The central nervous system and the gut microbiome
Sharon, G., Sampson, T. R., Geschwind, D. H., & Mazmanian, S. K. (2016) · Cell · doi:10.1016/j.cell.2016.10.027 · Cited by 1,513 · see citing works
Pharmacological Treatment of Parkinson Disease
Connolly, B. S., & Lang, A. E. (2014) · JAMA · doi:10.1001/jama.2014.3654 · Cited by 1,510 · see citing works
Signals from the gut microbiota to distant organs in physiology and disease
Schroeder, B. O., & Bäckhed, F. (2016) · Nature Medicine · doi:10.1038/nm.4185 · Cited by 1,409 · see citing works
Regulation of uric acid metabolism and excretion
Maiuolo, J., Oppedisano, F., Gratteri, S., Muscoli, C., & Mollace, V. (2015) · International Journal of Cardiology · doi:10.1016/j.ijcard.2015.08.109 · Cited by 1,405 · see citing works
Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice
Zhang, Y., Lee, F. Y., Barrera, G., Lee, H., Vales, C., Gonzalez, F. J., Willson, T. M., & Edwards, P. A. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506982103 · Cited by 951 · see citing works
Obeso, J. A., Stamelou, M., Goetz, C. G., Poewe, W., Lang, A. E., Weintraub, D., Burn, D., Halliday, G. M., Bezard, E., Przedborski, S., et al. (2017) · Movement Disorders · doi:10.1002/mds.27115 · Cited by 859 · cited 1× · see citing works
“Several therapies have been developed to relieve PDrelated symptoms, improving the patient's quality of life [5].”
BackgroundGenetics of Parkinson disease: paradigm shifts and future prospects
Farrer, M. J. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1831 · Cited by 709 · see citing works
Regulation of bile acid synthesis: pathways, nuclear receptors, and mechanisms
Chiang, J. Y. L. (2003) · Journal of Hepatology · doi:10.1016/j.jhep.2003.11.006 · Cited by 550 · see citing works
Serum Cholesterol in Young Men and Subsequent Cardiovascular Disease
Klag, M. J., Ford, D. E., Mead, L. A., He, J., Whelton, P. K., Liang, K., & Levine, D. M. (1993) · New England Journal of Medicine · doi:10.1056/nejm199302043280504 · Cited by 518 · see citing works
Metabolomic profiling to develop blood biomarkers for Parkinson's disease
Bogdanov, M. B., Matson, W. R., Wang, L., Matson, T., Saunders-Pullman, R. J., Bressman, S., & Beal, M. F. (2008) · Brain · doi:10.1093/brain/awm304 · Cited by 402 · see citing works
Plasma Urate and Risk of Parkinson's Disease
Weisskopf, M. G., O’Reilly, É. J., Chen, H., Schwarzschild, M. A., & Ascherio, A. (2007) · American Journal of Epidemiology · doi:10.1093/aje/kwm127 · Cited by 386 · see citing works
Urate as a Predictor of the Rate of Clinical Decline in Parkinson Disease
Ascherio, A. (2009) · Archives of Neurology · doi:10.1001/archneurol.2009.247 · Cited by 355 · see citing works
Small intestinal bacterial overgrowth in Parkinson's disease
Tan, A. H., Mahadeva, S., Thalha, A. M., Gibson, P. R., Kiew, C. K., Yeat, C. M., Ng, S. W., Ang, S. P., Chow, S. K., Tan, C. T., et al. (2014) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2014.02.019 · Cited by 274 · see citing works
Identification of novel biomarkers for Parkinson's disease by metabolomic technologies
Hatano, T., Saiki, S., Okuzumi, A., Mohney, R., & Hattori, N. (2015) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2014-309676 · Cited by 257 · see citing works
Membrane Cholesterol Dynamics: Cholesterol Domains and Kinetic Pools
Schroeder, F., Jefferson, J. R., Kier, A. B., Knittel, J. J., Scallen, T. J., Wood, W. G., & Hapala, I. (1991) · Experimental Biology and Medicine · doi:10.3181/00379727-196-43185 · Cited by 257 · see citing works
Gut microbiota in patients with Parkinson's disease in southern China
Lin, A., Zheng, W., He, Y., Tang, W., Wei, X., He, R., Huang, W., Su, Y., Huang, Y., Zhou, H., et al. (2018) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2018.05.007 · Cited by 253 · cited 1× · see citing works
“Most of metabolomic studies are based on the analysis of metabolites in cerebrospinal fluid (CSF) [8] and blood samples [9], although there are also some studies that have examined other biological samples such as urine [10, 11] or feces [12].”
BackgroundRecent advances and perspectives of metabolomics-based investigations in Parkinson’s disease
Shao, Y., & Le, W. (2019) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0304-2 · Cited by 239 · see citing works
Lrrk2 pathogenic substitutions in Parkinson's disease
Mata, I. F., Kachergus, J. M., Taylor, J. P., Lincoln, S., Aasly, J. O., Lynch, T., Hulihan, M., Cobb, S. A., Wu, R., Lu, C. S., et al. (2005) · Neurogenetics · doi:10.1007/s10048-005-0005-1 · Cited by 229 · see citing works
Observations on Serum Uric Acid Levels and the Risk of Idiopathic Parkinson's Disease
Davis, J. W., Grandinetti, A., Waslien, C., Ross, G. W., White, L. R., & Morens, D. M. (1996) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a008954 · Cited by 216 · see citing works
Total cholesterol and the risk of Parkinson disease
Hu, G., Antikaínen, R., Jousilahti, P., Kivipelto, M., & Tuomilehto, J. (2008) · Neurology · doi:10.1212/01.wnl.0000312511.62699.a8 · Cited by 205 · see citing works
Serum Cholesterol Levels and the Risk of Parkinson's Disease
de Lau, L. M. L., Koudstaal, P. J., Albert Hofman, D., & Breteler, M. M. B. (2006) · American Journal of Epidemiology · doi:10.1093/aje/kwj283 · Cited by 205 · see citing works
Ahmed, S. S. S. J., Santosh, W., Kumar, S., & Christlet, H. T. T. (2009) · Journal of Biomedical Science · doi:10.1186/1423-0127-16-63 · Cited by 197 · see citing works
Safety and Acceptability of the Research Lumbar Puncture
Peskind, E. R., Riekse, R. G., Quinn, J. F., Kaye, J. A., Clark, C. M., Farlow, M. R., DeCarli, C. S., Chabal, C., Vavrek, D. A., Raskind, M. A., et al. (2005) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000194014.43575.fd · Cited by 191 · see citing works
Lower low‐density lipoprotein cholesterol levels are associated with Parkinson's disease
Huang, X., Chen, H., Miller, W. C., Mailman, R. B., Woodard, J. L., Chen, P., Xiang, D., Murrow, R. W., Wang, Y., & Poole, C. (2006) · Movement Disorders · doi:10.1002/mds.21290 · Cited by 189 · see citing works
The LRRK2 G2019S mutant exacerbates basal autophagy through activation of the MEK/ERK pathway
Pedro, J. M. B., Niso‐Santano, M., Gómez‐Sánchez, R., Pizarro‐Estrella, E., Aiastui, A., Gorostidi, A., Climent, V. E., de Maturana, R. L., Sánchez‐Pernaute, R., de Munaín, A. L., et al. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1061-y · Cited by 175 · see citing works
Self-citation3‐hydroxykynurenine and other Parkinson's disease biomarkers discovered by metabolomic analysis
LeWitt, P. A., Li, J., Lü, M., Beach, T. G., Adler, C. H., & Guo, L. (2013) · Movement Disorders · doi:10.1002/mds.25555 · Cited by 174 · see citing works
Cholesterol metabolism in the brain and its association with Parkinson’s disease.
Jin, U., Park, S. J., & Park, S. M. (2019) · Experimental Neurobiology · doi:10.5607/en.2019.28.5.554 · Cited by 169 · see citing works
Marksteiner, J., Blasko, I., Kemmler, G., Koal, T., & Humpel, C. (2017) · Metabolomics · doi:10.1007/s11306-017-1297-5 · Cited by 158 · see citing works
Metabolomic Profiling in LRRK2-Related Parkinson's Disease
Johansen, K. K., Wang, L., Aasly, J. O., White, L. R., Matson, W. R., Henchcliffe, C., Beal, M. F., & Bogdanov, M. B. (2009) · PLoS ONE · doi:10.1371/journal.pone.0007551 · Cited by 155 · see citing works
Alternations of Metabolic Profile and Kynurenine Metabolism in the Plasma of Parkinson’s Disease
Chang, K., Cheng, M., Tang, H.-Y., Huang, C.-Y., Wu, Y., & Chen, C. (2018) · Molecular Neurobiology · doi:10.1007/s12035-017-0845-3 · Cited by 153 · see citing works
Metabolomic biomarkers as strong correlates of Parkinson disease progression
LeWitt, P. A., Li, J., Lü, M., Guo, L., & Auinger, P. (2017) · Neurology · doi:10.1212/wnl.0000000000003663 · Cited by 145 · see citing works
Urate: A Novel Biomarker of Parkinson‘s Disease Risk, Diagnosis and Prognosis
Cipriani, S., Chen, X. M., & Schwarzschild, M. A. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.10.94 · Cited by 142 · see citing works
Andreadou, E., Nikolaou, C., Gournaras, F., Rentzos, M., Boufidou, F., Tsoutsou, A., Zournas, C., Zissimopoulos, V., & Vassilopoulos, D. (2009) · Clinical Neurology and Neurosurgery · doi:10.1016/j.clineuro.2009.06.012 · Cited by 137 · see citing works
LC–MS-Based Urinary Metabolite Signatures in Idiopathic Parkinson’s Disease
Luan, H., Liu, L., Meng, N., Tang, Z., Chua, K.-K., Chen, L., Song, J., Mok, V., Xie, L.-X., Li, M., et al. (2014) · Journal of Proteome Research · doi:10.1021/pr500807t · Cited by 134 · see citing works
Huang, X., Abbott, R. D., Petrovitch, H., Mailman, R. B., & Ross, G. W. (2008) · Movement Disorders · doi:10.1002/mds.22013 · Cited by 124 · see citing works
A metabolic profile of polyamines in parkinson disease: A promising biomarker
Saiki, S., Sasazawa, Y., Fujimaki, M., Kamagata, K., Kaga, N., Taka, H., Li, Y., Souma, S., Hatano, T., Imamichi, Y., et al. (2019) · Annals of Neurology · doi:10.1002/ana.25516 · Cited by 123 · see citing works
N370S ‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease
García‐Sanz, P., Orgaz, L., Bueno-Gil, G., Espadas, I., Rodríguez‐Traver, E., Kulisevsky, J., Gutiérrez, A., Dávila, J. C., González‐Polo, R. A., Fuentes, J. M., et al. (2017) · Movement Disorders · doi:10.1002/mds.27119 · Cited by 121 · see citing works
Self-citationPotential biomarkers of Parkinson's disease revealed by plasma metabolic profiling
Zhao, H., Wang, C., Zhao, N., Li, W., Yang, Z., Liu, X., Le, W., & Zhang, X. (2018) · Journal of Chromatography B · doi:10.1016/j.jchromb.2018.01.025 · Cited by 102 · see citing works
Gout and the risk of parkinson's disease: A cohort study
Vera, M. A. D., Rahman, M. M., Rankin, J., Kopec, J. A., Gao, X., & Choi, H. K. (2008) · Arthritis Care & Research · doi:10.1002/art.24193 · Cited by 101 · see citing works
Serum caffeine and metabolites are reliable biomarkers of early Parkinson disease
Fujimaki, M., Saiki, S., Li, Y., Kaga, N., Taka, H., Hatano, T., Ishikawa, K., Oji, Y., Mori, A., Okuzumi, A., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000004888 · Cited by 100 · see citing works
Brain cholesterol metabolism and Parkinson's disease
Huang, X., Sterling, N. W., Du, G., Sun, D., Stetter, C. M., Kong, L., Zhu, Y., Neighbors, J. D., Lewis, M. M., Chen, H., et al. (2019) · Movement Disorders · doi:10.1002/mds.27609 · Cited by 80 · see citing works
The serum lipid profile of Parkinson's disease patients: a study from China
Guo, X., Song, W., Chen, K. G., Chen, X., Zheng, Z., Cao, B., Huang, R., Zhao, B., Wu, Y., & Shang, H. (2014) · International Journal of Neuroscience · doi:10.3109/00207454.2014.979288 · Cited by 68 · see citing works
Ikeda, K., Nakamura, Y., Kiyozuka, T., Aoyagi, J., Hirayama, T., Nagata, R., Ito, H., Iwamoto, K., Murata, K., Yoshii, Y., et al. (2011) · Neurodegenerative Diseases · doi:10.1159/000323265 · Cited by 66 · see citing works
Metabolomic Profiling of Bile Acids in an Experimental Model of Prodromal Parkinson’s Disease
Graham, S. F., Rey, N. L., Ugur, Z., Yilmaz, A., Sherman, E., Maddens, M., Bahado-Singh, R. O., Becker, K., Schulz, E., Meyerdirk, L. K., et al. (2018) · Metabolites · doi:10.3390/metabo8040071 · Cited by 60 · see citing works
Impaired Mitophagy and Protein Acetylation Levels in Fibroblasts from Parkinson’s Disease Patients
Yakhine-Diop, S. M. S., Niso‐Santano, M., Rodríguez‐Arribas, M., Gómez‐Sánchez, R., Martínez-Chacón, G., Uribe-Carretero, E., Navarro‐García, J. A., Ruiz‐Hurtado, G., Aiastui, A., Cooper, J. A. D., et al. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1206-6 · Cited by 59 · see citing works
Self-citationYakhine-Diop, S. M. S., Pedro, J. M. B., Gómez‐Sánchez, R., Pizarro‐Estrella, E., Rodríguez‐Arribas, M., Climent, V. E., Aiastui, A., de Munaín, A. L., Fuentes, J. M., & González‐Polo, R. A. (2014) · Toxicology · doi:10.1016/j.tox.2014.07.001 · Cited by 51 · see citing works
Self-citationRole of Serum Cholesterol in Parkinson's Disease: A Meta-Analysis of Evidence
Gudala, K., Bansal, D., & Muthyala, H. (2013) · Journal of Parkinson s Disease · doi:10.3233/jpd-130196 · Cited by 50 · see citing works
Reduced but not oxidized cerebrospinal fluid glutathione levels are lowered in Lewy body diseases
Maetzler, W., Schmid, S. P., Wurster, I., Liepelt, I., Gaenslen, A., Gasser, T., & Berg, D. (2010) · Movement Disorders · doi:10.1002/mds.23358 · Cited by 48 · see citing works
Hasuike, Y., Endo, T., Koroyasu, M., Matsui, M., Mori, C., Yamadera, M., Fujimura, H., & Sakoda, S. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109436 · Cited by 42 · see citing works
Morales-Garcia, J. A., Morante, D. A., Hernández-Encinas, E., Alonso‐Gil, S., Gil, C., Martı́nez, A., Santos, Á., & Pérez‐Castillo, A. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.10.008 · Cited by 41 · see citing works
Self-citationGout and the risk of Parkinson’s disease in older adults: a study of U.S. Medicare data
Singh, J. A., & Cleveland, J. D. (2019) · BMC Neurology · doi:10.1186/s12883-018-1234-x · Cited by 38 · see citing works
Kim, A., Nigmatullina, R. R., Zalyalova, Z. A., Soshnikova, N. V., Краснов, А. Н., Vorobyeva, N. E., Georgieva, S. G., Кудрин, В. С., Наркевич, В. Б., & Ugrumov, M. V. (2018) · Molecular Neurobiology · doi:10.1007/s12035-018-1315-2 · Cited by 37 · see citing works
Elevated excretion of biopyrrin as a new marker for idiopathic Parkinson's disease
Luan, H., Liu, L., Tang, Z., Mok, V., Li, M., & Cai, Z. (2015) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2015.09.009 · Cited by 23 · see citing works
Metabolomics and the search for biomarkers in Parkinson's disease
Amara, A. W., & Standaert, D. G. (2013) · Movement Disorders · doi:10.1002/mds.25644 · Cited by 11 · see citing works
Einarsson, K., Bergström, M., Eklöf, R., Nord, C. E., & Björkhem, I. (1992) · Scandinavian Journal of Clinical and Laboratory Investigation · doi:10.3109/00365519209088378 · Cited by 11 · see citing works
Fruit flies, bile acids, and Parkinson disease
Greenamyre, J. T., Sanders, L. H., & Gasser, T. (2015) · Neurology · doi:10.1212/wnl.0000000000001912 · Cited by 8 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases
Loh, J. S., Mak, W. Q., Tan, L. K. S., Ng, C. X., Chan, H. H., Yeow, S. H., Foo, J. B., Ong, Y. S., How, C. W., & Khaw, K. Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01743-1 · Cited by 1,193 · see citing works
The role of PARP1 in neurodegenerative diseases and aging
Mao, K., & Zhang, G. (2022) · The FEBS Journal · doi:10.1111/febs.15716 · Cited by 172 · see citing works
Lipid pathway dysfunction is prevalent in patients with Parkinson’s disease
Galper, J., Dean, N. J., Pickford, R., Lewis, S. J. G., Halliday, G. M., Kim, W. S., & Dzamko, N. L. (2022) · Brain · doi:10.1093/brain/awac176 · Cited by 159 · see citing works
Sun, N., Zhang, J., Wang, J., Liu, Z., Wang, X., Kang, P., Yang, C., Liu, P., & Zhang, K. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13368 · Cited by 102 · see citing works
Chen, S., & Lin, C. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00839-6 · Cited by 81 · see citing works
Bile acid receptors and signaling crosstalk in the liver, gut and brain
Ferrell, J. M., & Chiang, J. Y. L. (2021) · Liver Research · doi:10.1016/j.livres.2021.07.002 · Cited by 69 · see citing works
The pathogenesis of gut microbiota in hepatic encephalopathy by the gut–liver–brain axis
Zhu, R., Liu, L., Zhang, G., Dong, J., Ren, Z., & Li, Z. (2023) · Bioscience Reports · doi:10.1042/bsr20222524 · Cited by 56 · see citing works
Connecting the Gut Microbiota and Neurodegenerative Diseases: the Role of Bile Acids
Wang, S., Xu, C., Liu, H., Wei, W., Zhou, X., Qian, H., Zhou, L., Zhang, H., Wu, L. M., Chen, Z., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-023-03340-9 · Cited by 50 · see citing works
Gut microbiota and derived metabolomic profiling in glaucoma with progressive neurodegeneration
Zhang, Y., Zhou, X., & Lu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.968992 · Cited by 41 · see citing works
Metabolic Diffusion in Neuropathologies: The Relevance of Brain-Liver Axis
Vegas‐Suárez, S., Simón, J., Martínez‐Chantar, M. L., & Moratalla, R. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.864263 · Cited by 33 · see citing works
Luo, X., Liu, Y., Balck, A., Klein, C., & Fleming, R. M. T. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00732-z · Cited by 34 · see citing works
Linking Nonalcoholic Fatty Liver Disease and Brain Disease: Focusing on Bile Acid Signaling
Ren, Z., Li, C.-X., Ma, C., Chen, D., Chen, J., Xu, W., Chen, C.-A., Cheng, F., & Wang, X. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232113045 · Cited by 32 · see citing works
Liver’s influence on the brain through the action of bile acids
Yeo, X. Y., Tan, L. Y., Chae, W. R., Lee, D., Lee, Y., Wüestefeld, T., & Jung, S. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1123967 · Cited by 33 · see citing works
LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease
Galper, J., Kim, W. S., & Dzamko, N. L. (2022) · Biomolecules · doi:10.3390/biom12111597 · Cited by 29 · see citing works
Dahabiyeh, L. A., Nimer, R. M., Wells, J. D., Abu-rish, E. Y., & Fiehn, O. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30452 · Cited by 27 · see citing works
Drug Repurposing for Parkinson’s Disease: The International Linked Clinical Trials experience
Stott, S., Wyse, R. K. H., & Brundin, P. (2021) · Frontiers in Neuroscience · doi:10.3389/fnins.2021.653377 · Cited by 27 · see citing works
Metabolic Alterations in a Drosophila Model of Parkinson’s Disease Based on DJ-1 Deficiency
Solana‐Manrique, C., Sanz, F., Torregrosa, I., Palomino‐Schätzlein, M., Hernández-Oliver, C., Pineda‐Lucena, A., & Paricio, N. (2022) · Cells · doi:10.3390/cells11030331 · Cited by 27 · see citing works
Purine metabolites and complex diseases: role of genes and nutrients
Nelson, K. L., & Voruganti, V. S. (2021) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/mco.0000000000000764 · Cited by 25 · see citing works
Metabolomics in Parkinson’s Disease and Correlation with Disease State
Ostrakhovitch, E. A., Ono, K., & Yamasaki, T. R. (2025) · Metabolites · doi:10.3390/metabo15030208 · Cited by 24 · see citing works
Kiriyama, Y., & Nochi, H. (2023) · Genes · doi:10.3390/genes14040825 · Cited by 22 · see citing works
Metabolomics Unveils Disrupted Pathways in Parkinson’s Disease: Toward Biomarker-Based Diagnosis
dos Santos, W. T., Neto, A. K., Viana, G. S., Ferreira, M. S., Martins, L. C., Vale, T. C., Murgu, M., Dias, D. F., Soares, M. G., Chagas‐Paula, D. A., et al. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00355 · Cited by 22 · see citing works
Santos‐Lobato, B. L., Gardinassi, L. G., Bortolanza, M., Peti, A. P. F., Pimentel, Â. V., Faccioli, L. H., Bel, E. A. D., & Tumas, V. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02625-1 · Cited by 21 · see citing works
Zhang, Y., Sun, X., Zhang, Y., Kang, Z., Cai, L., Ding, J., Lu, M., & Hu, G. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106459 · Cited by 21 · see citing works
Albillos, S. M., Montero, O., Calvo, S., Solano-Vila, B., Trejo, J. M., & Cubo, E. (2021) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2021.09.014 · Cited by 18 · see citing works
Shima, S., Mizutani, Y., Yoshimoto, J., Maeda, Y., Ohdake, R., Nagao, R., Maeda, T., Higashi, A., Ueda, A., Ito, M., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00785-0 · Cited by 17 · see citing works
Pursuing Multiple Biomarkers for Early Idiopathic Parkinson’s Disease Diagnosis
Gopar‐Cuevas, Y., Duarte-Jurado, A. P., Diaz-Perez, R., Cárdenas, O. S., Loera‐Arias, M. D. J., Montes‐de‐Oca‐Luna, R., Rodríguez‐Rocha, H., & García‐García, A. (2021) · Molecular Neurobiology · doi:10.1007/s12035-021-02500-z · Cited by 17 · see citing works
The role of brain–liver–gut Axis in neurological disorders
Li, P., Xie, L., Yang, W., Feng, S., Mao, W., Ye, L., Cheng, H., Wu, X., & Mao, X. (2025) · Burns & Trauma · doi:10.1093/burnst/tkaf011 · Cited by 16 · see citing works
Zhang, M., Li, C., Ren, J., Wang, H., Fang, Y., Wu, J., & Tang, Y. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.909303 · Cited by 16 · see citing works
Santos-Rebouças, C. B., Cotrin, J. C., & dos Santos, G. C. (2023) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2023.111875 · Cited by 15 · see citing works
The Intricate Interplay: Microbial Metabolites and the Gut‐Liver‐Brain Axis in Parkinson's Disease
Kishanchand, D. K., A., A. K. K., Chandrababu, K., Philips, C. A., Sivan, U., & Chakrapani, P. S. B. (2025) · Journal of Neuroscience Research · doi:10.1002/jnr.70016 · Cited by 11 · see citing works
Ageing, proteostasis, and the gut: Insights into neurological health and disease
Akbar, M., Toppo, P., & Nazir, A. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102504 · Cited by 10 · see citing works
Decoding TGR5: A comprehensive review of its impact on cerebral diseases
Zhang, Z., Zhang, Y., Peng, H., Yu, Q., Kang, X., Liu, Y., Zheng, Y., Cheng, F., Wang, X., & Li, F. (2025) · Pharmacological Research · doi:10.1016/j.phrs.2025.107671 · Cited by 10 · see citing works
Thermodynamic Signatures of Blood Plasma Proteome in Neurodegenerative Pathologies
Danailova, A., Todinova, S. J., Gartcheva, L., Bogdanova, D., Zlatareva, E., Kalaydzhiev, N., Milanov, I. G., Krumova, S., & Taneva, S. G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010789 · Cited by 8 · see citing works
Yuluğ, B., Altay, Ö., Li, X., Hanoğlu, L., Çankaya, Ş., Lam, S. C. C., Yang, H., Coşkun, E., İdil, E., Nogaylar, R., et al. (2021) · medRxiv · doi:10.1101/2021.07.28.21261293 · Cited by 7 · see citing works
Neto, D. P. A., de Godoy, J. V. P., Tostes, K., Bosque, B. P., Rodrigues, P. V., Rocco, S. A., Sforça, M. L., & Fonseca, M. D. C. (2023) · Neuroscience · doi:10.1016/j.neuroscience.2023.06.010 · Cited by 5 · see citing works
Microbiota–gut–brain axis and bile acids–driven neuromodulation
Dong, T., Zhang, T., Wang, H., Zhang, J., Abdullah, R., Sun, B., & Peng, G. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-25-00927 · Cited by 4 · see citing works
Bile acids as therapeutic agents
Vu, B., Kawamoto, R., Villalba‐Davila, P., Dong, X., & Karnsakul, W. W. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1732854 · Cited by 4 · see citing works
Modeling of Parkinson’s disease in Drosophila based on DJ-1 deficiency
Sanz, F., Solana‐Manrique, C., & Paricio, N. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-89833-1.00043-4 · Cited by 4 · see citing works
Haghshenas, L., Banihashemi, S., Malekzadegan, Y., Catanzaro, R., Ahmadi, A. M., & Marotta, F. (2024) · World Journal of Gastrointestinal Pathophysiology · doi:10.4291/wjgp.v15.i5.96446 · Cited by 4 · see citing works
Shtanova, L. Y., Yanchuk, P. I., Veselsky, S. P., Tsymbalyuk, О. V., Vovkun, T. V., Москвина, В. С., Shablykina, O. V., Кравченко, А. А., Vm, B., & Khilya, V. P. (2021) · Fìzìologìčnij žurnal · doi:10.15407/fz67.04.064 · Cited by 3 · see citing works
Gender-associated differences in serum metabolite profiles among patients with Parkinson’s DiseasePreprint
Marino, C., Carrillo, F., Nuzzo, T., Vidali, M., Serra, M., Pietracupa, S., Modugno, N., Grimaldi, M., D’Ursi, A. M., Errico, F., et al. (2025) · medRxiv · doi:10.1101/2025.10.30.25339159 · Cited by 3 · see citing works
Marino, C., Carrillo, F., Nuzzo, T., Serra, M., Yahyavi, I., Grimaldi, M., Pietracupa, S., Modugno, N., Errico, F., D’Ursi, A. M., et al. (2025) · medRxiv · doi:10.1101/2025.11.20.25340670 · Cited by 3 · see citing works
Suga, N., Ikeda, Y., Yoshikawa, S., & Matsuda, S. (2023) · Exploration of Medicine · doi:10.37349/emed.2023.00180 · Cited by 2 · see citing works
Predtechenskaya, E. V., Rogachev, A. D., & Melnikova, P. M. (2024) · Acta Naturae · doi:10.32607/actanaturae.27511 · Cited by 2 · see citing works
Shtanova, L. Y., Veselsky, S. P., Yanchuk, P. I., Tsymbalyuk, О. V., Москвина, В. С., Shablykina, O. V., Moroz, O. F., Vovkun, T. V., Kravchenko, О. V., & Khilya, V. P. (2022) · Fìzìologìčnij žurnal · doi:10.15407/fz68.06.018 · Cited by 2 · see citing works
Fleming, R. M. T., Luo, X., Liu, Y., Balck, A., & Klein, C. (2023) · Research Square · doi:10.21203/rs.3.rs-3209421/v1 · Cited by 2 · see citing works
Sodders, M., Okorie, E., Tahmasebidehkordi, H., Marathi, A., Kumari, N., Lakhani, M., Schiro, A., Shen, M., Sriram, N., Sarkar, S., et al. (2024) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2024.05.15.594309 · Cited by 2 · see citing works
Revisiting cirrhosis-related parkinsonism: a comprehensive review
Fernández-Garza, L. E., Torres, L. A. G., Estrada-Bellmann, I. E., Cortéz-Hernández, C. A., Fernández-Garza, V. A., Nomura-Quiroz, R. P., & Navarrete-Rodríguez, A. (2026) · Metabolic Brain Disease · doi:10.1007/s11011-026-01875-z · Cited by 1 · see citing works
Uric Acid and Purine Recycling Disorders in Parkinson’s Disease: A Cross-Sectional StudyPreprint
Shima, S., Mizutani, Y., Yoshimoto, J., Maeda, Y., Ohdake, R., Nagao, R., Maeda, T., Higashi, A., Ueda, A., Ito, M., et al. (2023) · Preprints.org · doi:10.20944/preprints202311.0450.v1 · Cited by 1 · see citing works
Marino, C., Carrillo, F., Serra, M., Nuzzo, T., Vidali, M., Pietracupa, S., Modugno, N., Grimaldi, M., Errico, F., D’Ursi, A. M., et al. (2026) · medRxiv · doi:10.64898/2026.01.13.26344011
- Authors
- Yakhine-Diop, S. M. S., Morales-García, J. A., Niso-Santano, M., González-Polo, R. A., Uribe-Carretero, E., Martinez-Chacon, G., Durand, S., Maiuri, M. C., Aiastui, A., Zulaica, M., Ruíz-Martínez, J., López de Munain, A., Pérez-Tur, J., Pérez-Castillo, A., Kroemer, G., Bravo-San Pedro, J. M., & Fuentes, J. M.
- Affiliations
- Biomedical Research Networking Center on Neurodegenerative Diseases (ES)
- Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas (CIBERNED), Madrid, Spain
- Departamento de Bioquímica y Biología Molecular y Genética. Facultad de Enfermería y Terapia Ocupacional. Universidad de Extremadura, Cáceres, Spain
- Metabolomics and Cell Biology Platforms, Institut Gustave Roussy, Villejuif, France
- Inserm (FR)
- Karolinska University Hospital (SE)
- Corresponding author
- Fuentes, José M.
- ORCID
- Venue
- Aging
- Publisher
- Impact Journals, LLC
- Published
- 2020-09-09
- Volume
- 12
- Issue
- 17
- Pages
- 16690-16708
- ISSN
- 1945-4589 (ISSN-L)
- PMC
- PMC7521510
- OpenAlex
- W3083883133
- Cited by
- 50
- References
- 62
- Citations by year
- 2026: 3 · 2025: 7 · 2024: 9 · 2023: 10 · 2022: 12 · 2021: 9
- FWCI
- 3.36
- Type
- journal article
- Language
- en
- Open access
- green
- hdl.handle.net
- Licence
- cc-by
- Locations
- Aging (publishedVersion)
- PubMed (publishedVersion)
- Institutional Repository University of Extremadura (University of Extremadura) (submittedVersion, cc-by)
- Communities in ADDI (University of the Basque Country) (submittedVersion, other-oa)
- DIGITAL.CSIC (Spanish National Research Council (CSIC)) (submittedVersion, cc-by-nc-nd)
- LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas) (submittedVersion, cc-by)
- Hispana (submittedVersion, cc-by)
- Funders
- Association pour la Recherche sur le Cancer (ANR-18-IDEX-0001)
- Seerave Foundation (ANR-18-IDEX-0001)
- E-Rare
- European Commission
- Agence Nationale de la Recherche (ANR-18-IDEX-0001)
- Fondation Leducq
- Institut National de la Santé et de la Recherche Médicale (UMS3655, ANR-18-IDEX-0001)
- Fondation pour la Recherche Médicale (ANR-18-IDEX-0001)
- Ministerio de Educación, Cultura y Deporte (FPU16/00684, RYC-2016-20883, FPU16)
- Fundación para la Formación y la Investigación de los Profesionales de la Salud de Extremadura
- Ligue Contre le Cancer (ANR-18-IDEX-0001)
- Centre National de la Recherche Scientifique (#ANR-18-IDEX-0001, UMS3655)
- Institut Universitaire de France (ANR-18-IDEX-0001)
- Institut National Du Cancer (#ANR-18-IDEX-0001)
- Institut Gustave-Roussy (UMS3655)
- Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (GDW20171100085, RYC-2016-20883, FPU16/00684, CB06/05/0041, 2015/03, CB06/05/1123, ANR-18-IDEX-0001, RYC-2018-025099-I, PI15/0034, SAF2017-85199-P, SAF2014-52940-R)
- European Research Area Network on Cardiovascular Diseases
- Fundación Isabel Gemio (CB06/05/0041, FPU16/00684)
- Instituto de Salud Carlos III (SAF2014-52940-R, FPU16/00684, SAF2017-85199-P, ANR-18-IDEX-0001, PI19/01653)
- European Regional Development Fund (SAF2014-52940-R, SAF2017, SAF2017-85199-P, CB06/05/0041, 2015/03)
- High-end Foreign Experts Recruitment Plan of China (GDW20171100085)
- Labex Immuno-Oncology ((ANR-18-IDEX-0001))
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolomics and Mass Spectrometry Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Clinical Biochemistry › Metabolism and Genetic Disorders
- Keywords
- Parkinson's disease, plasma metabolomics, bile acids, purine metabolism, hypoxanthine, cholic acid, deoxycholic acid, lithocholic acid, 6-hydroxydopamine, familial Parkinson's disease, idiopathic Parkinson's disease, biomarkers, diagnosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
